Clinical Trial Update: Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ustekinumab for prevention of acute graft-versus-host disease in patients undergoing unrelated donor hematopoietic cell transp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING